プラチナ製剤を含む治療に失敗した局所進行性または転移性非小細胞肺癌患者を対象とした、アテゾリズマブとドセタキセルの比較研究

基本情報

NCT ID

NCT02008227

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,225

治験依頼者名

Hoffmann-La Roche

概要

This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

対象疾患

介入

依頼者（Sponsor）

実施施設 (15)